PATIENT ALERT: Information regarding Coronavirus (COVID-19).  

Clinical Research & Trials

USO 18232

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)


Disease Types: Breast Cancer Research, GYN Cancer Research

Eligibility Requirements:

  • Measurable disease
  • Must be negative for Hep B, Hep C, and HIV at screening
  • No condition or surgery that impairs drug absorption such as GI dysfunction or gastric bypass
  • No autoimmune disease that required systemic treatment in last 2 years, vitiligo and resolved asthma/atopy exceptions

Available at: